Congenital Adrenal Hyperplasia (CAH) – Market Access and Reimbursement Insights Report – 2025

Congenital Adrenal Hyperplasia (CAH) Market Access and Reimbursement Insights

Thelansis’s “Congenital Adrenal Hyperplasia (CAH) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Congenital Adrenal Hyperplasia (CAH) Overview

Congenital adrenal hyperplasia (CAH) encompasses seven autosomal recessive disorders resulting from gene mutations that encode enzymes in cortisol production pathways. These enzymes include 21-hydroxylase (21OH), 11β-hydroxylase (11βOH), 17α-hydroxylase (17OH, also known as 17,20-lyase), 3β-hydroxysteroid dehydrogenase type 2 (3βHSD2), steroidogenic acute regulatory protein (StAR), P450 cholesterol side-chain cleavage enzyme (SCC), and P450 oxidoreductase (POR). This genetic variation leads to hormonal imbalances and clinical and biochemical phenotypes in individuals with CAH, which can involve alterations in glucocorticoid, mineralocorticoid, and sex steroid production. The impact of CAH varies among individuals. There are different forms of CAH, with the most common being ‘classic CAH,’ typically diagnosed through newborn screening.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Congenital Adrenal Hyperplasia (CAH) – Market Access and Reimbursement Insights Report – 2025